ROR1 is an Intriguing Target for Cancer Therapy
暂无分享,去创建一个
[1] L. Giménez,et al. ROR1 contributes to melanoma cell growth and migration by regulating N‐cadherin expression via the PI3K/Akt pathway , 2016, Molecular carcinogenesis.
[2] J. Lambert,et al. New developments for antibody-drug conjugate-based therapeutic approaches. , 2016, Current opinion in immunology.
[3] Yu-Sun Chang,et al. Expression of ROR1 has prognostic significance in triple negative breast cancer , 2016, Virchows Archiv.
[4] G. Widhopf,et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. , 2015, The Journal of clinical investigation.
[5] Young Chul Kim,et al. Alternative Wnt Signaling Activates YAP/TAZ , 2015, Cell.
[6] G. Widhopf,et al. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. , 2015, Clinical lymphoma, myeloma & leukemia.
[7] A. I. Imani Fooladi,et al. An In silico Chimeric Vaccine Targeting Breast Cancer Containing Inherent Adjuvant , 2015, Iranian journal of cancer prevention.
[8] S. Riddell,et al. Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells , 2014, Cancer Immunology Research.
[9] N. Borcherding,et al. ROR1, an embryonic protein with an emerging role in cancer biology , 2014, Protein & Cell.
[10] F. de Marinis,et al. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. , 2014, Translational lung cancer research.
[11] A. Weeraratna,et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.
[12] A. Porwit,et al. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies , 2013, Leukemia & lymphoma.
[13] Terry P Yamaguchi,et al. Wnt5a Potentiates TGF-β Signaling to Promote Colonic Crypt Regeneration After Tissue Injury , 2012, Science.
[14] C. Turtle,et al. Engineered T cells for anti-cancer therapy. , 2012, Current opinion in immunology.
[15] W. Wilson,et al. Targeting malignant B cells with an immunotoxin against ROR1 , 2012, mAbs.
[16] Tomoya Yamaguchi,et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. , 2012, Cancer cell.
[17] J. Wang-Rodriguez,et al. ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth , 2012, PloS one.
[18] K. Kwong,et al. Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies , 2011, PloS one.
[19] Thomas M. Schmitt,et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. , 2010, Blood.
[20] Jeffrey P. MacKeigan,et al. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance , 2005, Nature Cell Biology.